-
EDAP TMS S.A. (EDAP) files $125M mixed shelf
-
EDAP reports record 2025 HIFU revenue, issues 2026 guidance
-
EDAP TMS S.A. (EDAP) PT Raised to $2 at Jefferies
-
EDAP receives French reimbursement for prostate cancer HIFU treatment
-
EDAP TMS S.A. (EDAP) PT Lowered to $14 at H.C. Wainwright
-
EDAP TMS S.A. (EDAP) Presents Positive Results from the FARP Randomized Controlled Trial
-
EDAP TMS S.A. (EDAP) To Launch New Focal One i Robotic HIFU system
-
Jefferies Downgrades EDAP TMS S.A. (EDAP) to Hold
-
Piper Sandler Sees EDAP TMS S.A. (EDAP) as 'Undervalued'; PT Lowered to $4.50
-
H.C. Wainwright Reiterates Buy Rating on EDAP TMS S.A. (EDAP)
-
EDAP TMS S.A. (EDAP) Appoints Glen French to its Board
-
EDAP TMS S.A. (EDAP) Appoints Joshua H. Levine to Board of Directors
-
EDAP (EDAP) Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology
-
Senti Biosciences (SNTI) Appoints Fran Schulz to its Board
-
EDAP TMS S.A. (EDAP) PT Lowered to $5 at Piper Sandler
-
EDAP TMS S.A. (EDAP) Misses Q3 EPS by 1c
-
EDAP TMS S.A. (EDAP) Announces First Patients Treated in Phase I/II Study Evaluating Focal One Robotic HIFU for the Treatment of Benign Prostatic Hyperplasia
-
EDAP TMS S.A. (EDAP) Misses Q2 EPS by 6c
-
EDAP TMS S.A. (EDAP) Reports Interim Results from Phase 3 Study of Robotic HIFU
-
EDAP TMS S.A. (EDAP) Appoints Fran Schulz to its Board

